Techno Medica Co., Ltd.

6678 株式会社テクノメディカ

Medical Devices · Standard · TSE: Disclosed

PRICE: ¥2,009 · MKT CAP: ¥17.6B · P/E: 12.9x · P/B: 0.93x · DIV YIELD: 3.4%

PRICE — 5Y

Characteristics & Business Summary

Techno Medica Co., Ltd. engages in the research and development, manufacture, sale, import, and export of in-vitro diagnostic analyzers in Japan. The company offers automated tube selecting and labeling systems, RFID process control system, blood and urine...

Income Statement Highlights (¥ Million, except EPS/DPS in ¥)

Fiscal Period	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Forecast
Net Sales	9,040	9,699	9,368	10,284	9,906	11,237	4,270
Operating Profit	1,608	1,862	1,649	1,840	1,300	1,668	170
Ordinary Profit	1,630	1,851	1,668	1,871	1,304	1,718	—
Net Profit	1,153	1,281	1,151	1,348	1,005	1,071	120
EPS	¥132	¥146	¥131	¥154	¥115	¥122	—
DPS	¥51	¥60	¥60	¥68	¥68	¥0	—

Balance Sheet & Valuation Highlights

Total Assets ¥18B

Net Assets (Equity) ¥14B

Equity Ratio 80.2%

ROE (Return on Equity) 7.4%

Cash & Equivalents ¥9B

Interest-Bearing Debt —

Capital Expenditure (CapEx) ¥0B

Depreciation & Amort. ¥0B

Major Shareholders

1. 株式会社オートニクス 14.0%
2. 實吉繁幸 13.2%
3. The Master Trust Bank of Japan, Ltd. (Trust Account) 7.0%
4. Nomura Trust and Banking Co., Ltd. 5.5%
5. Northern Trust Company 5.2%
6. 平澤修 3.5%
7. THE HONGKONG AND SHANGHAI BANKING CORPORATION LIMITED-HONG KONG PRIVATE BANKING DIVISION CLIENT A/C 8028-394841（常任代理人香港上海銀行東京支店カストディ業務部） 3.2%
8. 實吉政知 3.1%
9. テクノメディカ従業員持株会 2.2%
10. 高良明 1.7%

Activist Activity

Masatomo Saneyoshi 9.61%

2026-02-10 · correction

Masatomo Saneyoshi 9.61%

2026-02-09 · change

Masatomo Saneyoshi 13.03%

2026-02-02 · initial_5pct

VARECS Partners Limited 0.31%

2023-12-22 · change

United Managers Japan Inc. 0.0%

2023-12-22 · exit

Historical Per-Share Data & Valuation Ratios

Per Share Metric	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Forecast
Revenues per share	¥1,032	¥1,107	¥1,069	¥1,174	¥1,131	¥1,283	—
FCF/Share	¥91	¥228	¥86	¥126	¥109	¥122	—
EPS	¥132	¥146	¥131	¥154	¥115	¥122	—
DPS	¥51	¥60	¥60	¥68	¥68	¥0	—
Capital Spending per share	¥3	¥8	¥15	¥4	¥3	¥4	—
Book Value per share	¥1,708	¥1,787	¥1,871	¥1,577	¥1,643	¥1,645	—
Common Shares Outstanding	9M	9M	9M	9M	9M	—	—

Financial Aggregates & Margins

Financial Aggregate	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Forecast
Revenues (Net Sales)	¥9B	¥10B	¥9B	¥10B	¥10B	¥11B	¥4B
Operating Margin (%)	17.8%	19.2%	17.6%	17.9%	13.1%	14.8%	4.0%
Net Profit (owners)	¥1B	¥1B	¥1B	¥1B	¥1B	¥1B	¥0B
Net Profit Margin (%)	12.8%	13.2%	12.3%	13.1%	10.1%	9.5%	2.8%
Working Capital	¥13B	¥14B	¥14B	¥11B	¥12B	¥12B	—
Total Debt (Interest-bearing)	¥0B	¥0B	¥0B	¥0B	¥0B	—	—
Net Worth (Common Equity)	¥15B	¥16B	¥16B	¥14B	¥14B	¥14B	—
Return on Total Assets (ROA)	6.6%	6.9%	5.9%	7.7%	5.6%	6.0%	—
Return on Common Equity (ROE)	7.7%	8.2%	7.0%	9.8%	7.0%	7.4%	—

Business Summary & Analysis

Capital Strategy Targets

No active capital policy disclosure records found.